The US Food and Drug Administration approved a second vaccine on 31 May to protect older adults against infection from the respiratory syncytial virus (RSV). The vaccine, Abrysvo, was developed by Pfizer Inc and is expected to be launched before the next RSV season which typically starts in the autumn and peaks in the winter. The decision follows the agency’s authorisation on 3 May of a vaccine for the same disease from GSK Plc.
